<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768702</url>
  </required_header>
  <id_info>
    <org_study_id>C3BS-C-11-01</org_study_id>
    <secondary_id>2011-001117-13</secondary_id>
    <nct_id>NCT01768702</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.</brief_title>
  <acronym>CHART-1</acronym>
  <official_title>Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celyad (formerly named Cardio3 BioSciences)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celyad (formerly named Cardio3 BioSciences)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to
      standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy between groups post-index procedure</measure>
    <time_frame>39 weeks post-index</time_frame>
    <description>Change between groups from baseline and 39 weeks in a hierarchical composite outcome comprising, from most to least severe outcome, days to death from any cause, number of worsening of heart failure events, change in score for the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (10-point deterioration, no meaningful change,10-point improvement), change in six-minute walk distance (40-m deterioration, no meaningful change, 40-m improvement) and change in left ventricular end systolic volume (15-mL deterioration, no meaningful change, 15-mL improvement), and left ventricular ejection fraction (4% absolute deterioration, no meaningful change, 4% absolute improvement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and safety between groups post-index procedure</measure>
    <time_frame>52 and 104 weeks post-index</time_frame>
    <description>Safety: Number and cause of deaths and re-admissions, number of cardiac transplantations, number of myocardial infarctions, number of strokes. Incidence of serious adverse events (AE) through week 104 and non-serious AEs (through week 52).
Efficacy: Time to all cause mortality, time to worsening of heart failure, and time to aborted sudden death through week 52.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy and safety between groups post-index procedure</measure>
    <time_frame>39 and 52 weeks post-index</time_frame>
    <description>Time to all cause mortality, time to cardiovascular mortality, and rate of worsening heart failure requiring outpatient IV therapy for heart failure or readmission for heart failure, and others.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham, no injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3BS-CQR-1 Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of C3BS-CQR-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection of C3BS-CQR-1</intervention_name>
    <description>Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.</description>
    <arm_group_label>C3BS-CQR-1 Treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sham, no injection</intervention_name>
    <description>Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible patients must meet all of the following inclusion criteria:

          1. Age ≥ 18 and &lt; 80 years.

          2. Systolic dysfunction with left ventricular ejection fraction (LVEF) ≤ 35% as assessed
             by echocardiography.

          3. Ischemic heart failure without known need for revascularization.

          4. Total MLHFQ score &gt; 30.

          5. Ability to perform a 6 minute walk test &gt; 100 m and ≤ 400 m.

          6. History of hospitalization for heart failure (HF) within 12 months prior to screening
             or treatment in an outpatient clinic with intravenous vasoactive therapy (including
             vasodilators, positive inotropic agents and vasopressors) or diuretics for worsening
             Heart Failure within 12 months prior to screening.

          7. Be or must have been within the previous 12 months in New York Heart Association
             (NYHA) Class III or IV or Interagency Registry for Mechanically Assisted Circulatory
             Support (INTERMACS) class 4, 5, 6 or 7, and at the time of inclusion, must be at least
             in NYHA Class II or greater.

          8. Use of ACE inhibitor and/or angiotensin receptor blocker (ARB); and beta blocker, for
             at least 3 months prior to screening visit, unless intolerant or contraindicated.

          9. Stable dosing of ACE inhibitor, angiotensin receptor blocker , beta blocker,
             aldosterone blocker,and diuretics for at least one month prior to screening visit,
             defined as ≤50% change in total dose of each agent.

         10. Willing and able to give written informed consent.

        Exclusion Criteria (summarized):

        Eligible patients must meet none of the following exclusion criteria:

          1. Women who are pregnant, confirmed by a positive urine or serum human chorionic
             gonadotropin laboratory test at screening.

          2. Women of child-bearing potential without a negative serum or urine pregnancy test at
             screening. Women who are postmenopausal (12 months of spontaneous amenorrhea or 6
             months of spontaneous amenorrhea with serum FSH level &gt; 40 mIU/mL or 6 weeks post
             surgical bilateral oophorectomy) or surgically sterile are not considered to be of
             child-bearing potential. Reliable contraception includes surgical sterilization,
             hormonal contraception, or doublebarrier methods.

          3. Men refusing to exercise a reliable form of contraception.

          4. Myocardial infarction, unstable angina or percutaneous coronary intervention (PCI)
             within 90 days prior to screening, or coronary artery bypass graft surgery within 180
             days prior to screening.

          5. Patient on a cardiac transplant list or previously received any solid organ
             transplant.

          6. Previously underwent cardiac surgery with remodeling procedure, left ventricular
             assist device placement or cardiomyoplasty. This exclusion does not apply to patients
             who underwent ventricularplasty without placement device more than one year ago.

          7. Patient has undergone cardiac resynchronization therapy within 6 months prior to
             screening.

          8. Severe uncontrolled HF requiring need for intensive intravenous diuretics or inotropic
             support within 1 month prior to screening.

          9. Inability to perform a 6 minute walk test due to physical limitations other than HF
             including:

               1. Severe peripheral vascular disease

               2. Severe pulmonary disease or chronic obstructive pulmonary disease limiting
                  exercise

               3. Orthopedic limitations, severe muscular diseases, any other joint or muscular
                  disease or neurological disorder (such as an old stroke or neuropathy) limiting
                  the ability to walk for 6 minutes.

         10. Dependence on chronic oral steroid therapy.

         11. Stroke or transient ischemic attack leading to limitations in lower extremities or
             occurring within 180 days prior to screening.

         12. Active myocarditis, constrictive pericarditis, restrictive, hypertrophic or congenital
             cardiomyopathy.

         13. BMI &lt; 19 or &gt; 45.

         14. Left ventricular thrombus.

         15. Left ventricular (LV) wall thickness &lt; 8mm visualized in more than 50% of LV, and
             defined as a &quot;LV no-go zone&quot;.

         16. LV aneurysm or candidate for surgical aneurysmectomy.

         17. Sustained ventricular tachycardia or ventricular fibrillation which led to automatic
             implantable cardioverter/defibrillator (AICD) therapy (shock) within 3 months prior to
             screening.

         18. Primary significant organic valvular heart disease.

         19. Moderate to severe aortic valve disease precluding catheter entry into the LV.

         20. Mechanical prosthetic valve in aortic or mitral position.

         21. Chronic infection or active malignancy.

         22. Patient has compromised renal function as reflected by a serum creatinine level &gt;3.0
             mg/dL (&gt;0.265 mmol/L) or is currently on dialysis.

         23. Hematocrit &lt; 28%.

         24. Atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree
             that could impede or preclude the safe retrograde passage of the delivery catheter.

         25. Chronic immunosuppressive therapy due to inflammatory or systemic disease.

         26. Patient tested positive for HIV 1 or 2, Hepatitis B or C, human T-cell lymphotrophic
             virus (HTLV) 1 or 2 (if required by regulations) or syphilis.

         27. Exposure to any previous experimental cell or angiogenic therapy and/or myocardial
             laser therapy and/or therapy with another investigational drug within 60 days prior to
             screening or enrollment in any concurrent study that may confound the results of this
             study.

         28. Known drug or alcohol dependence or any other factors which will interfere with the
             study conduct or interpretation of the results or in the opinion of the investigator
             are not suitable to participate.

         29. Any illness other than congestive heart failure which might reduce life expectancy to
             less than 2 years from screening.

         30. Known and relevant allergies and/or hypersensitivities to Dextran or other plasma
             volume expanders to include Gentran, Hyskon and Macrodex.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Terzic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic, Division of Cardiovascular Diseases, Rochester (MN, USA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jozef Bartunek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OLV Ziekenhuis Aalst (Belgium)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil Marie Curie</name>
      <address>
        <city>Lodelinsart</city>
        <zip>6042</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Glorieux</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinic Cardiology Center Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment 'Alexandrovska' EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet - Felnőtt Kardiológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Városmajori Szív- és Érgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MH Egészségügyi Központ Kardiológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos - és Egészségtudomanyi Centrum</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinikai Központ - Szívgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center - Cardiology Unit</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nazareth Hospital EMMS</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center - Heart Institute</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUI Verona - Borgo Trento Hospital</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, KliniczneCentrum Kardiologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-126</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Górnośląskie Centrum Medyczne Śląskiej Akademii Medycznej</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biegański Hospital</name>
      <address>
        <city>Łódź</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Emergency Internal Medicinne Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia - Cardiology Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Cardiology Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara - Cardiology Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa, Cardiology Dept.</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Kragujevac,</name>
      <address>
        <city>Kragujevac</city>
        <zip>34 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria - Campus de Teatinos s/n</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure of Ischemic Origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

